CRISPR/Cas9 for cancer research and therapy
CRISPR/Cas9 has become a powerful method for making changes to the genome of many organisms. First discovered in bacteria as part of an adaptive immune system, CRISPR/Cas9 and modified versions have found a widespread use to engineer genomes and to activate or to repress the expression of genes. As...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2019
|
| In: |
Seminars in cancer biology
Year: 2018, Jahrgang: 55, Pages: 106-119 |
| ISSN: | 1096-3650 |
| DOI: | 10.1016/j.semcancer.2018.04.001 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.semcancer.2018.04.001 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1044579X17302742 
|
| Verfasserangaben: | Tianzuo Zhan, Niklas Rindtorff, Johannes Betge, Matthias P. Ebert, Michael Boutros |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 166632499X | ||
| 003 | DE-627 | ||
| 005 | 20230427154404.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190527r20192018xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.semcancer.2018.04.001 |2 doi | |
| 035 | |a (DE-627)166632499X | ||
| 035 | |a (DE-599)KXP166632499X | ||
| 035 | |a (OCoLC)1341225493 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Zhan, Tianzuo |d 1985- |e VerfasserIn |0 (DE-588)1019998911 |0 (DE-627)691070105 |0 (DE-576)359019544 |4 aut | |
| 245 | 1 | 0 | |a CRISPR/Cas9 for cancer research and therapy |c Tianzuo Zhan, Niklas Rindtorff, Johannes Betge, Matthias P. Ebert, Michael Boutros |
| 264 | 1 | |c 2019 | |
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Available online 16 April 2018 | ||
| 500 | |a Gesehen am 27.05.2019 | ||
| 520 | |a CRISPR/Cas9 has become a powerful method for making changes to the genome of many organisms. First discovered in bacteria as part of an adaptive immune system, CRISPR/Cas9 and modified versions have found a widespread use to engineer genomes and to activate or to repress the expression of genes. As such, CRISPR/Cas9 promises to accelerate cancer research by providing an efficient technology to dissect mechanisms of tumorigenesis, identify targets for drug development, and possibly arm cells for cell-based therapies. Here, we review current applications of the CRISPR/Cas9 technology for cancer research and therapy. We describe novel Cas9 variants and how they are used in functional genomics to discover novel cancer-specific vulnerabilities. Furthermore, we highlight the impact of CRISPR/Cas9 in generating organoid and mouse models of cancer. Finally, we provide an overview of the first clinical trials that apply CRISPR/Cas9 as a therapeutic approach against cancer. | ||
| 534 | |c 2018 | ||
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Cas9 | |
| 650 | 4 | |a CRISPR | |
| 650 | 4 | |a Genome-engineering | |
| 650 | 4 | |a High-throughput screening | |
| 650 | 4 | |a Immune therapy | |
| 650 | 4 | |a Organoids | |
| 650 | 4 | |a Synthetic lethality | |
| 700 | 1 | |a Rindtorff, Niklas |d 1995- |e VerfasserIn |0 (DE-588)1163560782 |0 (DE-627)1027881793 |0 (DE-576)508051479 |4 aut | |
| 700 | 1 | |a Betge, Johannes |d 1986- |e VerfasserIn |0 (DE-588)108257421X |0 (DE-627)847674347 |0 (DE-576)455525021 |4 aut | |
| 700 | 1 | |a Ebert, Matthias |d 1968- |e VerfasserIn |0 (DE-588)1030133522 |0 (DE-627)734827083 |0 (DE-576)377938432 |4 aut | |
| 700 | 1 | |a Boutros, Michael |e VerfasserIn |0 (DE-588)1023031132 |0 (DE-627)717350045 |0 (DE-576)366291831 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Seminars in cancer biology |d London : Academic Press, 1995 |g 55(2019), Seite 106-119 |h Online-Ressource |w (DE-627)268128448 |w (DE-600)1471735-9 |w (DE-576)264423526 |x 1096-3650 |7 nnas |a CRISPR/Cas9 for cancer research and therapy |
| 773 | 1 | 8 | |g volume:55 |g year:2019 |g pages:106-119 |g extent:14 |a CRISPR/Cas9 for cancer research and therapy |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.semcancer.2018.04.001 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1044579X17302742 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190527 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1023031132 |a Boutros, Michael |m 1023031132:Boutros, Michael |d 60000 |e 60000PB1023031132 |k 0/60000/ |p 5 |y j | ||
| 998 | |g 1030133522 |a Ebert, Matthias |m 1030133522:Ebert, Matthias |d 60000 |d 61100 |e 60000PE1030133522 |e 61100PE1030133522 |k 0/60000/ |k 1/60000/61100/ |p 4 | ||
| 998 | |g 108257421X |a Betge, Johannes |m 108257421X:Betge, Johannes |d 60000 |d 61100 |e 60000PB108257421X |e 61100PB108257421X |k 0/60000/ |k 1/60000/61100/ |p 3 | ||
| 998 | |g 1163560782 |a Rindtorff, Niklas |m 1163560782:Rindtorff, Niklas |d 50000 |e 50000PR1163560782 |k 0/50000/ |p 2 | ||
| 998 | |g 1019998911 |a Zhan, Tianzuo |m 1019998911:Zhan, Tianzuo |d 60000 |d 61100 |e 60000PZ1019998911 |e 61100PZ1019998911 |k 0/60000/ |k 1/60000/61100/ |p 1 |x j | ||
| 999 | |a KXP-PPN166632499X |e 3479753779 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedKey":"1995","dateIssuedDisp":"1995-","publisher":"Academic Press","publisherPlace":"London"}],"pubHistory":["Nachgewiesen 6.1995 -"],"title":[{"title":"Seminars in cancer biology","title_sort":"Seminars in cancer biology"}],"note":["Gesehen am 21.02.20"],"recId":"268128448","id":{"zdb":["1471735-9"],"issn":["1096-3650"],"eki":["268128448"]},"language":["eng"],"part":{"extent":"14","volume":"55","pages":"106-119","text":"55(2019), Seite 106-119","year":"2019"},"disp":"CRISPR/Cas9 for cancer research and therapySeminars in cancer biology","physDesc":[{"extent":"Online-Ressource"}]}],"name":{"displayForm":["Tianzuo Zhan, Niklas Rindtorff, Johannes Betge, Matthias P. Ebert, Michael Boutros"]},"recId":"166632499X","id":{"doi":["10.1016/j.semcancer.2018.04.001"],"eki":["166632499X"]},"language":["eng"],"physDesc":[{"extent":"14 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"2019","dateIssuedKey":"2019"}],"person":[{"role":"aut","display":"Zhan, Tianzuo","family":"Zhan","given":"Tianzuo"},{"role":"aut","display":"Rindtorff, Niklas","given":"Niklas","family":"Rindtorff"},{"role":"aut","family":"Betge","given":"Johannes","display":"Betge, Johannes"},{"display":"Ebert, Matthias","family":"Ebert","given":"Matthias","role":"aut"},{"display":"Boutros, Michael","given":"Michael","family":"Boutros","role":"aut"}],"title":[{"title":"CRISPR/Cas9 for cancer research and therapy","title_sort":"CRISPR/Cas9 for cancer research and therapy"}],"note":["Available online 16 April 2018","Gesehen am 27.05.2019"]} | ||
| SRT | |a ZHANTIANZUCRISPRCAS92019 | ||